View the latest news and SEC filings
Scroll to
LONDON and RALEIGH, N.C., April 15, 2025 (GLOBE NEWSWIRE) — Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”) announces that it will report its financial results for the first quarter ended March 31, 2025 on Tuesday, April 29, 2025 and host an investment community conference call
RIPSA interests repurchased Term loan facility increased to $450 million with more favorable terms Access to up to an additional $200 million LONDON and RALEIGH, N.C., March 28, 2025 (GLOBE NEWSWIRE) — Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”), a biopharmaceutical company
Ohtuvayre TM (ensifentrine) recorded net product sales of $36.6 million in Q4 and $42.3 million in 2024 More prescriptions filled through February 2025 than in Q4 2024 Over 4,600 unique prescribers with ~55% of Tier 1 HCPs prescribing Ohtuvayre through February 2025 Phase 2 programs in
LONDON and RALEIGH, N.C., Feb. 18, 2025 (GLOBE NEWSWIRE) — Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”) announces that senior management will present a company overview at the following conferences in March 2025: TD Cowen 45 th Annual Health Care Conference Date: Monday,
| Date | Form | Filing Group | ||
|---|---|---|---|---|
|
April 26, 2017 |
EFFECT |
EFFECT |
Other |
|
|
April 26, 2017 |
EFFECT |
EFFECT |
Other |
|
|
April 26, 2017 |
Registration of up to an additional 20% of securities for an offering filed on an F-1 |
F-1MEF |
Registration Statements |
|
|
April 26, 2017 |
This filing is a pre-effective amendment to an F-1 filing |
F-1/A |
Registration Statements |
|
|
April 24, 2017 |
CORRESP |
CORRESP |
Other |
|
|
April 24, 2017 |
CORRESP |
CORRESP |
Other |
|
|
April 24, 2017 |
CORRESP |
CORRESP |
Other |
|
|
April 24, 2017 |
UPLOAD |
UPLOAD |
Other |
|
|
April 21, 2017 |
CERTNAS |
CERTNAS |
Other |
Verona Pharma (Nasdaq:VRNA) is focused on delivering our strategy and creating value for shareholders.
